• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report.

作者信息

He Xi, Jiao Xiao-Dong, Liu Ke, Qin Bao-Dong, Wu Ying, Ling Yan, Liu Jun, Xu A-Qiao, Song Kun, Zang Yuan-Sheng

机构信息

Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.

Shaoxing Central Hospital, Shaoxing, Zhejiang Province, China.

出版信息

JCO Precis Oncol. 2021 May 3;5. doi: 10.1200/PO.20.00534. eCollection 2021.

DOI:10.1200/PO.20.00534
PMID:34036227
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8140796/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f9/8140796/307cc5cee625/po-5-po.20.00534-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f9/8140796/934fc1b51cf6/po-5-po.20.00534-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f9/8140796/76ea2776c216/po-5-po.20.00534-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f9/8140796/342c4a5d200d/po-5-po.20.00534-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f9/8140796/307cc5cee625/po-5-po.20.00534-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f9/8140796/934fc1b51cf6/po-5-po.20.00534-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f9/8140796/76ea2776c216/po-5-po.20.00534-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f9/8140796/342c4a5d200d/po-5-po.20.00534-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f9/8140796/307cc5cee625/po-5-po.20.00534-g004.jpg

相似文献

1
Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report.ALK基因重排的转移性结直肠癌患者对克唑替尼、阿来替尼和劳拉替尼的临床反应：一例报告
JCO Precis Oncol. 2021 May 3;5. doi: 10.1200/PO.20.00534. eCollection 2021.
2
Response to lorlatinib on a patient with ALK-rearranged non-small cell lung cancer harboring 1151Tins mutation with uterine metastasis.对携带有子宫转移的 ALK 重排非小细胞肺癌患者 1151Tins 突变给予 lorlatinib 治疗的反应。
Thorac Cancer. 2021 Aug;12(16):2275-2278. doi: 10.1111/1759-7714.14056. Epub 2021 Jun 28.
3
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.针对晚期非小细胞肺癌中间变性淋巴瘤激酶酪氨酸激酶抑制剂的耐药谱：一项使用靶向下一代测序的多中心研究。
Eur J Cancer. 2021 Oct;156:1-11. doi: 10.1016/j.ejca.2021.06.043. Epub 2021 Aug 13.
4
Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.洛拉替尼治疗阿来替尼和布加替尼耐药的 ALK 阳性非小细胞肺癌脑膜转移患者的成功治疗：一例报告。
Medicine (Baltimore). 2021 Oct 1;100(39):e27385. doi: 10.1097/MD.0000000000027385.
5
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.比较伴有 ALK 重排的晚期非小细胞肺癌一线治疗的疗效和安全性：临床试验的荟萃分析。
BMC Cancer. 2021 Nov 26;21(1):1278. doi: 10.1186/s12885-021-08977-0.
6
Impact of ALK Inhibitors in Patients With -Rearranged Nonlung Solid Tumors.ALK 抑制剂在伴有 - Rearranged 非肺部实体瘤患者中的作用。
JCO Precis Oncol. 2021 May 3;5. doi: 10.1200/PO.20.00383. eCollection 2021.
7
Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.真实世界中lorlatinib 治疗晚期 ALK 阳性非小细胞肺癌患者的疗效和安全性。
Anticancer Drugs. 2021 Nov 1;32(10):1099-1104. doi: 10.1097/CAD.0000000000001107.
8
Metastatic Non-Myofibroblastic Sarcoma Harbouring EML4-ALK Fusion-Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations.转移性非肌纤维母细胞肉瘤伴 EML4-ALK 融合——对 ALK 酪氨酸激酶抑制剂的显著反应和耐药突变的发展。
Cancer Rep (Hoboken). 2024 Aug;7(8):e2164. doi: 10.1002/cnr2.2164.
9
Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor.由间变性淋巴瘤激酶抑制剂引起的皮肤肉瘤样药物反应。
J Cutan Pathol. 2021 Mar;48(3):425-428. doi: 10.1111/cup.13911. Epub 2020 Nov 15.
10
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.阿来替尼对比克唑替尼用于治疗初治的间变性淋巴瘤激酶阳性（ALK+）非小细胞肺癌：来自 ALEX 研究的中枢神经系统疗效结果。
Ann Oncol. 2018 Nov 1;29(11):2214-2222. doi: 10.1093/annonc/mdy405.

引用本文的文献

1
Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer.神经元碱性磷酸酶2及其碱性磷酸酶受体促成了结肠炎相关结直肠癌的发展。
Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2500632122. doi: 10.1073/pnas.2500632122. Epub 2025 Jun 10.
2
Case report: Dramatic impact of DNA next generation sequencing results using specific targeted therapies- and .病例报告：使用特定靶向疗法的DNA下一代测序结果的显著影响 - 以及 。 （注：原文最后“- and.”表述不完整，可能影响准确理解。）
Front Oncol. 2024 Nov 26;14:1462930. doi: 10.3389/fonc.2024.1462930. eCollection 2024.
3
Metastatic Non-Myofibroblastic Sarcoma Harbouring EML4-ALK Fusion-Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations.

本文引用的文献

1
First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer.一线劳拉替尼或克唑替尼治疗晚期阳性肺癌。
N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187.
2
Leptomeningeal metastasis from solid tumors.实体瘤的软脑膜转移
J Neurol Sci. 2020 Apr 15;411:116706. doi: 10.1016/j.jns.2020.116706. Epub 2020 Jan 23.
3
Basket Trials for Intractable Cancer.难治性癌症的篮式试验
转移性非肌纤维母细胞肉瘤伴 EML4-ALK 融合——对 ALK 酪氨酸激酶抑制剂的显著反应和耐药突变的发展。
Cancer Rep (Hoboken). 2024 Aug;7(8):e2164. doi: 10.1002/cnr2.2164.
4
Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis.探索结直肠癌中的ALK融合：病例系列及综合分析
NPJ Precis Oncol. 2024 May 13;8(1):100. doi: 10.1038/s41698-024-00598-7.
5
Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature Review.间变性淋巴瘤激酶（ALK）抑制剂在伴有ALK重排的结直肠癌中显示出活性：病例系列及文献综述
Oncologist. 2025 Jan 17;30(1). doi: 10.1093/oncolo/oyae020.
6
ALK fusions in the pan-cancer setting: another tumor-agnostic target?泛癌背景下的ALK融合：另一个不依赖肿瘤类型的靶点？
NPJ Precis Oncol. 2023 Sep 29;7(1):101. doi: 10.1038/s41698-023-00449-x.
7
Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.靶向结直肠癌耐药性和转移的分子机制：最新进展及展望。
World J Gastroenterol. 2023 Mar 7;29(9):1395-1426. doi: 10.3748/wjg.v29.i9.1395.
8
Anaplastic lymphoma kinase inhibitors and their effect on the kidney.间变性淋巴瘤激酶抑制剂及其对肾脏的影响。
Clin Kidney J. 2022 Feb 26;15(8):1475-1482. doi: 10.1093/ckj/sfac062. eCollection 2022 Aug.
9
Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy.结直肠癌异质性及其对精准医学和治疗效果的影响。
Biomedicines. 2022 Apr 30;10(5):1035. doi: 10.3390/biomedicines10051035.
10
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.ALK 抑制剂在 ALK 融合阳性胃肠道癌症患者中的应用：国际数据集和分子病例系列。
JCO Precis Oncol. 2022 Apr;6(1):e2200015. doi: 10.1200/PO.22.00015.
Front Oncol. 2019 Apr 12;9:229. doi: 10.3389/fonc.2019.00229. eCollection 2019.
4
[Report of cancer epidemiology in China, 2015].《2015年中国癌症流行病学报告》
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005.
5
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.脑脊液游离 DNA 作为液体活检在 ALK 重排 NSCLC 脑膜转移中的临床应用
J Thorac Oncol. 2019 May;14(5):924-932. doi: 10.1016/j.jtho.2019.01.007. Epub 2019 Jan 17.
6
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.富含高甲基化 MLH1 启动子和野生型 BRAF/KRAS 的结直肠肿瘤富含可靶向的激酶融合。
Cancer Res. 2019 Mar 15;79(6):1047-1053. doi: 10.1158/0008-5472.CAN-18-3126. Epub 2019 Jan 14.
7
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。
Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.
8
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
9
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.转移性结直肠癌中的 ALK、ROS1 和 NTRK 重排。
J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.
10
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment.瑞戈非尼治疗具有长期疗效的化疗难治性转移性结直肠癌患者的临床结局及分子特征
ESMO Open. 2017 Jul 29;2(3):e000177. doi: 10.1136/esmoopen-2017-000177. eCollection 2017.